Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Mutations At The FLT3 Activation Loop D835 Residue Confer Differential Resistance To Clinically Active FLT3 Inhibitors

Kimberly Lin, BS, Catherine C Smith, MD, Sara Salerno, PharmD, Neil P. Shah, MD, PhD

Blood (2013) 122 (21): 3929.

https://doi.org/10.1182/blood.V122.21.3929.3929

Published: 2013

Journal Articles

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Kimberly C. Lin, Whitney K. Stewart, Lauren E. Damon, Sara Salerno, Neil P. Shah

Blood (2013) 121 (16): 3165–3171.

https://doi.org/10.1182/blood-2012-07-442871

Published: 2013

Includes: Supplemental data

Journal Articles

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220

Catherine C Smith, MD, Jason Chin, PhD, Elisabeth Lasater, PhD, Amy L. Paguirigan, PhD, Kimberly Lin, BS, Whitney Stewart, BS, Sara Salerno, BS, Lauren E Damon, Mark J. Levis, MD, PhD, Alexander E Perl, MD, Kevin Travers, PhD, Andrew Kasarskis, PhD, Jerald P. Radich, MD, Neil Shah, MD, PhD

Blood (2012) 120 (21): 674.

https://doi.org/10.1182/blood.V120.21.674.674

Published: 2012

Journal Articles

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Warren Fiskus, BSc, PhD, Catherine C. Smith, MD, Jacqueline Smith, MS, Scott C. Wise, MS, Elisabeth Lasater, PhD, Lauren E. Damon, Sara Salerno, BS, Allan Fleming, MD, Ruben Reyes, MD, Siddhartha Ganguly, MD, Mark S. Berger, MD, Tom J. Rutkoski, Ph.D, Joseph McGuirk, DO, Neil Shah, MD, PhD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 2611.

https://doi.org/10.1182/blood.V118.21.2611.2611

Published: 2011

Journal Articles

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,

Catherine C. Smith, MD, Michael Brown, PhD, Jason Chin, PhD, Corynn Kasap, BS, Sara Salerno, BS, Lauren E. Damon, Kevin Travers, PhD, Susana Wang, Andrew Kasarskis, PhD, Eric Schadt, PhD, Neil Shah, MD, PhD

Blood (2011) 118 (21): 3752.

https://doi.org/10.1182/blood.V118.21.3752.3752

Published: 2011

Journal Articles

Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants

Catherine C. Smith, MD, Lauren E. Damon, Xiaotian Zhu, PhD, Sara Salerno, BS, Neil Shah, MD, PhD

Blood (2011) 118 (21): 930.

https://doi.org/10.1182/blood.V118.21.930.930

Published: 2011

Journal Articles

Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia

Catherine C. Smith, MD, Jason Chin, PhD, Qi Wang, PhD, Sara Salerno, BS, Lauren E. Damon, Jeremy P. Hunt, Mark J. Levis, MD, PhD, Alexander E Perl, MD, Kevin Travers, PhD, Susana Wang, Andrew Kasarskis, PhD, Eric Schadt, PhD, John Kuriyan, PhD, Neil Shah, MD, PhD

Blood (2011) 118 (21): 937.

https://doi.org/10.1182/blood.V118.21.937.937

Published: 2011

NARROW

Mutations At The FLT3 Activation Loop D835 Residue Confer Differential Resistance To Clinically Active FLT3 Inhibitors

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,

Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants

Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Mutations At The FLT3 Activation Loop D835 Residue Confer Differential Resistance To Clinically Active FLT3 Inhibitors

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220

Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations

Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,

Analysis of in Vitro Activity of the Clinically-Active ABL/FLT3 Inhibitor Ponatinib (AP24534) Against AC220-Resistant FLT3-ITD Mutants

Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only